Sulkin, R and Karlsson, R and Whitington, T and Aly, M and Gronberg, H and Eeles, RA and Easton, RA and Kote-Jarai, Z and Al Olama, AA and Benlloch, S and Muir, K and Giles, GG and Southey, MC and Fitzgerald, LM and Henderson, BE and Schumacher, FR and Haiman, CA and Sipeky, C and Tammela, TL and Nordestgaard, BG and Key, TJ and Travis, RC and Neal, DE and Donovan, JL and Hamdy, FC and Pharaoh, PD and Pashayan, N and Khaw, KT and Stanford, JL and Thibodeau, SN and McDonnell, SK and Schaid, DJ and Majer, C and Vogel, W and Luedeke, M and Herkommer, K and Kibel, AS and Cybulski, C and Lubinski, J and Kluzniak, W and Cannon--Albright, L and Brenner, H and Herrmann, V and Holleczek, B and Park, JY and Sellers, TA and Lim, HY and Slavov, C and Kaneva, RP and Mitev, VI and Spurdle, A and Teixeira, MR and Paulo, P and Maia, S and Pandha, H and Michael, A and Kierzek, A and Batra, J and Clements, JA and Andriole, GL and Berndt, SI and Chanock, S and Gapstur, SM and Giovannucci, EL and Hunter, DJ and Kraft, P and Le Marchand, L and Ma, J and Mondul, AM and Penney, KL and Stampfer, MJ and Stevens, VL and Weinstein, SJ and Trichopoulou, A and Bueno-de-Mesquita, BH and Tionneland, A and Cox, DG and Maehle, L and Schleutker, J and Lindstrom, S and Wiklund, F, PRACTICAL consortium; Australian Prostate Cancer BioResource; BPC3 consortium, Genome-Wide Association Study of Prostate Cancer-Specific Survival, Cancer Epidemiology, Biomarkers and Prevention, 24, (11) pp. 1796-1800. ISSN 1055-9965 (2015) [Refereed Article]
© 2015 American Association for Cancer Research
BACKGROUND: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical.
METHODS: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR).
RESULTS: We observed no significant association between genetic variants and prostate cancer survival.
CONCLUSIONS: Common genetic variants with large impact on prostate cancer survival were not observed in this study.
IMPACT: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.
|Item Type:||Refereed Article|
|Keywords:||Prostate Cancer GWAS|
|Research Division:||Medical and Health Sciences|
|Research Group:||Oncology and Carcinogenesis|
|Research Field:||Cancer Genetics|
|Objective Group:||Clinical Health (Organs, Diseases and Abnormal Conditions)|
|Objective Field:||Cancer and Related Disorders|
|Author:||Fitzgerald, LM (Dr Liesel Fitzgerald)|
|Web of Science® Times Cited:||9|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page